07/09/2026
Online claims that reishi mushroom surpasses melatonin for treating chronic insomnia lack credible scientific backing at least no publicly available abstract or peer-reviewed trial from the SLEEP 2026 meeting currently validates such a conclusion. The circulating post describes an eight-week randomized trial comparing 5 mg of melatonin against reishi extract standardized to 6% triterpenes, but without details on study title, participant count, results, statistical rigor, adverse events, or funding, it is impossible to evaluate whether reishi truly outperformed melatonin. An abstract represents preliminary data only, and absent an accessible, peer-reviewed publication, asserting superiority for one treatment over the other would be irresponsible. While melatonin has demonstrated benefit for certain circadian rhythm disturbances, chronic insomnia is frequently more complex than a simple phase-shift problem.
Sleep medicine specialists increasingly view chronic insomnia as a multifactorial condition involving hyperarousal, maladaptive sleep behaviors, stress, comorbid medical illnesses, pain, anxiety, depression, or concurrent sleep disorders like obstructive sleep apnea. Reishi supplements themselves exhibit considerable variability in dosage and purity, and established medical references warn of potential side effects and drug interactions notably increased bleeding risk when combined with anticoagulants and reports of hepatotoxicity. Pregnant individuals, those with pre-existing liver disease, and patients using medications for diabetes, hypertension, or coagulation should avoid self-medicating with reishi without first consulting a healthcare professional. Cognitive behavioral therapy for insomnia (CBT-I) remains the best-evidenced first-line intervention for chronic insomnia disorder, and individuals experiencing persistent sleep difficulties lasting three months or longer particularly when daytime functioning is impaired should seek professional medical guidance rather than relying on unverified supplement claims.